Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

HCW Biologics shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration ...

HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...

HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...

In recent trading, Hcw Biologics Inc (HCWB) stock price has shown some volatility, fluctuating 92.70% over the last five trades and 42.55% over the past 30 trades. This represents a notable shift from ...

MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company with a market capitalization of approximately $12.4 million, announced today that it has received U.S.

HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to ...

HCW Biologics Inc. shares have reached a new 52-week low, trading at $0.25, as the company faces a challenging market environment. According to InvestingPro data, the company's financial health score ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation ...

Dr. Hing C. Wong, the Founder and CEO of HCW Biologics, is participating as a panelist at the prestigious 2025 GenScript Biotech Global Forum, highlighting the company's expertise and commitment ...